Dapsone and schistocytes: Thrombotic microangiopathy or not?
PLOS One · 22.05.2026 · 21 (5) · e0349570
DOI: 10.1371/journal.pone.0349570 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS One, online erschienen am 22.05.2026. Verfasst von Alexis Archambeaud und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, CHU Tours, Tours, France. Hauptthemen laut MEDLINE: Dapsone, Erythrocytes, Abnormal, Thrombotic Microangiopathies. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Dapsone is used in many infectious and immunological diseases. Dapsone may cause haemolysis, particularly in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. This hemolysis is described as oxidative and is usually not associated with the presence of schistocytes. Patients and methods We conducted a single-centre retrospective observational study at the University Hospital of Tours, France (2005–2021). Adult patients who received dapsone and had a blood smear performed during treatment or within 7 days of discontinuation were included. Data were extracted from electronic medical records. Patients were classified as schistocyte-positive (≥0.1%) or -negative. Descriptive statistics were used; no further analyses were performed due to small sample size.
Results
During the 2005−2021 period, 19 adult patients received dapsone in our institution. Amongst them, 10 (52.6%) had detectable schistocytes, ranging from 2 to 44/1000 erythrocytes (13 ± 14.2). Patients with schistocytosis exhibited more severe hemolytic anemia, with a larger decrease in hemoglobin (−2.7 ± 1.4 g/dL vs −1.6 ± 2.12 g/dL), higher methemoglobinemia (5.2% vs 1.9%), more frequent low haptoglobin levels (88.9% vs 60%), and elevated LDH levels (557 U/L [239–671] vs 273 U/L [208–507]) compared to patients without schistocytosis. Platelet counts were similar between the two groups. No organ failure was identified in the reviewed medical records. Schistocytosis regressed upon discontinuation of treatment after 3–18 days.
Conclusion
Dapsone appears to be associated with hemolytic anemia and the presence of schistocytes, suggesting mechanical intravascular haemolytic anaemia. Whether Dapsone-associated biological thrombotic microangiopathy can be associated with target organ damage requires further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, CHU Tours, Tours, France.
- Department of Haematology, CHU Tours, Tours, France.
- University of Tours, INSERM ISCHEMIA U 1327, Tours, France.
- University of Tours, University of Nantes, INSERM 1246-SPHERE, Tours; CHU Tours, Regional Pharmacovigilance Centre, Tours, France.
- Department of Nephrology, CHU Tours, Tours, France.
ORCID-Profile: Alexis Archambeaud
Zitieren
APA
Archambeaud, A., Aumont, C., Pouplard, C., Agier, M. S., Maillot, F., Halimi, J. M., & Bigot, A. (2026). Dapsone and schistocytes: Thrombotic microangiopathy or not?. PLOS One, 21(5), e0349570. https://doi.org/10.1371/journal.pone.0349570
Vancouver
Archambeaud A, Aumont C, Pouplard C, Agier MS, Maillot F, Halimi JM, et al. Dapsone and schistocytes: Thrombotic microangiopathy or not?. PLOS One. 2026;21(5):e0349570. doi:10.1371/journal.pone.0349570
BibTeX
@article{Archambeaud2026,
author = {Archambeaud, Alexis and Aumont, Cédric and Pouplard, Claire and Agier, Marie-Sarah and Maillot, François and Halimi, Jean-Michel and Bigot, Adrien},
title = {Dapsone and schistocytes: Thrombotic microangiopathy or not?},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {5},
pages = {e0349570},
doi = {10.1371/journal.pone.0349570}
}
EUVIMED